Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus Treated by Autologous Hematopoietic Stem Cell Transplantation.

医学 造血干细胞移植 抗磷脂综合征 狼疮抗凝剂 移植 环磷酰胺 人口 内科学 免疫学 胃肠病学 血栓形成 外科 化疗 环境卫生
作者
Laisvyde Statkute,Richard K. Burt,Yu Oyama,Larissa Verda,Nela Krosnjar,Ann E Traynor
出处
期刊:Blood [Elsevier BV]
卷期号:104 (11): 1877-1877 被引量:3
标识
DOI:10.1182/blood.v104.11.1877.1877
摘要

Abstract The association of antiphospholipid antibodies (APLA) with either vascular thrombosis or fetal morbidity is known as the antiphospholipid syndrome (APS). Since systemic lupus erythematosus (SLE) is frequently associated with APS, we analyzed 44 patients with severe and refractory SLE involved in a larger study of autologous hematopoietic stem cell transplantation (HSCT) utilizing cyclophosphamide and antithymocyte globulin (ATG) conditioning to determine the efficacy of this treatment in eliminating APLA and preventing recurrent thrombi. The prevalence of SLE-related APS in our patient population was 63% (45% met Sapporo criteria for definite APS, and 18% had history of APLA positivity with associated clinical APS features). Nineteen patients with APS had lupus anticoagulant (LA) and/or high titers of anticardiolipin antibodies (ACLA) at the entry into study. Ten patients were positive for LA. Fourteen patients showed elevated titers of ACLA, IgG and/or IgM. When followed for up to 30 months after autologous HSCT, 70% of initially LA-positive patients became and remained negative for anticoagulant. 79% demonstrated normalization of ACLA titers during maximum of 28 months follow-up. 64% of patients refractory to chronic anticoagulation regimen were able to discontinue from anticoagulation therapy at average of 6 months post-transplant and remained thrombotic events-free and in complete SLE remission for up to 78 months after HSCT. There was no treatment-related mortality or severe adverse events, including stem cell engrafment-related hematological complications or overhelming bacterial, fungal or viral infection, in any of the 28 SLE-related APS patient. Autologous hematopoietic stem cell transplantation may be performed safely and appears to be effective therapy for eliminating SLE-related APLA and preventing further thrombotic events.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
羊粑粑的应助被PPP采纳,获得100
刚刚
JamesPei的应助被是个狼火采纳,获得10
刚刚
无极微光的应助被敏感远望采纳,获得20
1秒前
1秒前
嘀嘀完成签到,获得积分10
1秒前
共享精神的应助被黑妹采纳,获得10
1秒前
搜集达人的应助被TALE采纳,获得10
1秒前
1秒前
1秒前
幽默枫发布了新的文献求助10
1秒前
CC完成签到,获得积分10
2秒前
2秒前
汉堡包的应助被刘承昭采纳,获得10
2秒前
秋风的应助被雪维采纳,获得20
2秒前
jzhou65发布了新的文献求助10
2秒前
3秒前
3秒前
yk发布了新的文献求助10
3秒前
材料人完成签到,获得积分10
3秒前
研友_VZG7GZ的应助被刀疤尤金采纳,获得30
3秒前
3秒前
4秒前
什么虾仁蛋挞完成签到,获得积分10
4秒前
Anoxia完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
马少兴发布了新的文献求助10
5秒前
5秒前
zhaodan完成签到,获得积分10
5秒前
英俊的铭的应助被JueR采纳,获得10
5秒前
6秒前
年轻幻柏发布了新的文献求助10
6秒前
从容盼旋发布了新的文献求助30
7秒前
Anoxia发布了新的文献求助10
7秒前
aa的应助被科研通管家采纳,获得10
7秒前
林小昀发布了新的文献求助10
7秒前
领导范儿的应助被科研通管家采纳,获得10
7秒前
我是老大的应助被科研通管家采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741